ResearcherUniversity of North TexasNo recent work listed
Myrna Hurtado
Matched on ORCID iD 0000-0003-0704-8384; OpenAlex author ID A5026504263. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper
Papers 4
- Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells. Co-author DOI 10.1016/j.procbio.2019.10.022↗
- Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2018.03.016↗
- Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors. Co-author DOI 10.1159/000495715↗
- Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.14651↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Umesh T. Sankpal · 4 shared papers, 2017–2020 · strength 0.35
- Paper Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic a… DOI 10.1016/j.procbio.2019.10.022↗
- Paper Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. DOI 10.1016/j.critrevonc.2018.03.016↗
- Paper Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. DOI 10.18632/oncotarget.14651↗
- Riyaz M. Basha · 4 shared papers, 2017–2020 · strength 0.35
- Paper Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic a… DOI 10.1016/j.procbio.2019.10.022↗
- Paper Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. DOI 10.1016/j.critrevonc.2018.03.016↗
- Paper Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. DOI 10.18632/oncotarget.14651↗
- Amalendu Prakash Ranjan · 1 shared paper, 2018 · strength 0.09
- Ganji Purnachandra Nagaraju · 1 shared paper, 2018 · strength 0.09
- Bassel F. El‐Rayes · 1 shared paper, 2018 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.